Apr 30, 2019   SOURCE: PR NewsWire

Array BioPharma to Report Financial Results for the Third Quarter of Fiscal 2019 on May 7, 2019

BOULDER, Colo., April 30, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, May 7, 2019 at 9:00 am ET. 

                        Date:         
            Tuesday, May 7, 2019


                        Time:         
            9:00 a.m. Eastern Time


                        Toll-Free:    
            (844) 464-3927


                        Toll:         
            (765) 507-2598


                        Pass Code:                                3638409




                        Webcast, including Replay and Conference Call Slides:


                        https://edge.media-server.com/m6/p/bt2tyqof

About Array BioPharma
Array BioPharma Inc. is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets BRAFTOVI(®) (encorafenib) capsules in combination with MEKTOVI(®) (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF(V600E) or BRAF(V600K) mutation in the United States and with partners in other major worldwide markets. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant metastatic colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), LOXO-292 (partnered with Loxo Oncology), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797. Vitrakvi(®) (larotrectinib, partnered with Loxo Oncology) is approved in the United States and Ganovo(®) (danoprevir, partnered with Roche) is approved in China. For more information on Array, please visit www.arraybiopharma.com or follow @arraybiopharma on Twitter and LinkedIn.

CONTACT:
Array BioPharma
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate Communications
(303) 381-6600
ir@arraybiopharma.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-third-quarter-of-fiscal-2019-on-may-7-2019-300840936.html

SOURCE Array BioPharma Inc.